Truxima
Scope
Date
~
-
Bio & Pharma
Celltrion to deliver three treatments to Peru
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...
Feb 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Jan 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion signs largest-ever quarterly deal with global sales affiliate
Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...
Sep 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Truxima shows safety, efficacy in post-marketing study
South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...
Feb 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires approval to sell Vegzelma in Canada
South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)